Breaking News

Pfizer Completes Acquisition of Arena Pharmaceuticals

Pfizer Completes Acquisition of Arena Pharmaceuticals

Acquisition delivers new, differentiated, and likely finest-in-course tactic to deal with demands of a broader quantity of individuals with immuno-inflammatory conditions

NEW YORK, March 11, 2022–(Organization WIRE)–Pfizer Inc. (NYSE: PFE) announced nowadays the completion of its acquisition of Arena Prescription drugs, a medical stage enterprise developing modern potential therapies for the remedy of various immuno-inflammatory illnesses.

Arena Pharmaceuticals brings to Pfizer a portfolio of assorted and promising improvement-phase therapeutic candidates in gastroenterology, dermatology, and cardiology, which includes etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator at present in development for a array of immuno-inflammatory illnesses like ulcerative colitis, Crohn’s Ailment, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.

“We are excited to add the extraordinary working experience and pipeline of Arena Prescription drugs to Pfizer’s Irritation and Immunology therapeutic space, encouraging us even more our reason of building breakthroughs to alter the life of all those with immuno-inflammatory conditions,” said Mike Gladstone, World-wide President & Common Supervisor, Pfizer Inflammation and Immunology. “In distinct, we’re hopeful that we can speed up scientific progress of etrasimod successfully to have a favourable impression on those people residing with these debilitating illnesses.”

Arena has formerly indicated that it predicted the benefits of the Stage 3 ELEVATE-UC trial of etrasimod in ulcerative colitis during the initially quarter of 2022.

Arena’s pipeline also incorporates two progress-stage cardiovascular assets: temanogrel for microvascular obstruction and Raynaud’s phenomenon secondary to systemic sclerosis, and APD418 for acute coronary heart failure.

Further Transaction Facts

Pfizer has done its acquisition of all outstanding shares, alternatives, and restricted stock models of Arena for $100 for every share, in income, for a total equity benefit of approximately $6.7 billion. The acquisition was completed by way of a merger in accordance with Delaware regulation and, as a outcome of the acquisition, Arena turned a wholly-owned subsidiary of Pfizer. In relationship with the acquisition, Arena’s shares of popular inventory will be delisted from the Nasdaq International Select Market place on or about March 11, 2022.

For additional background on the acquisition, make sure you examine the announcement push launch listed here.

About Pfizer Inflammation & Immunology
At Pfizer Swelling & Immunology, we strive to deliver breakthroughs that permit independence from working day-to-working day suffering for people dwelling with autoimmune and chronic inflammatory illnesses, which can be debilitating, disfiguring and distressing, significantly impacting what they can do. With a aim on immuno-inflammatory conditions in Rheumatology, Gastroenterology and Clinical Dermatology, our latest portfolio of authorized medications and investigational molecules spans a number of action and shipping and delivery mechanisms, from topicals to small molecules, biologics and biosimilars. The root induce of several immunological health conditions is immuno-swelling, which demands specially designed agents. Our differentiated R&D tactic resulted in a person of the broadest pipelines in the sector, where we purposefully match molecules to disorders exactly where we imagine they can make the largest variance. Creating on our many years-very long commitment and pioneering science, we continue on to progress the conventional of treatment for sufferers living with immuno-inflammatory diseases and are working hand-in-hand with sufferers, caregivers and the broader healthcare group on healthcare methods for the several worries of running persistent inflammatory ailments, enabling people to stay their ideal lives.

Pfizer Inc.: Breakthroughs that Improve Patients’ Lives
At Pfizer, we apply science and our world wide means to convey therapies to people today that extend and appreciably strengthen their lives. We attempt to established the standard for quality, safety, and price in the discovery, advancement, and manufacture of well being care merchandise, including progressive medicines and vaccines. Every day, Pfizer colleagues work throughout made and rising markets to advance wellness, avoidance, treatment options, and cures that obstacle the most feared illnesses of our time. Regular with our obligation as one particular of the world’s leading impressive biopharmaceutical businesses, we collaborate with health and fitness care companies, governments, and neighborhood communities to help and broaden entry to reputable, affordable wellbeing treatment all over the planet. For additional than 170 many years, we have worked to make a difference for all who rely on us. We routinely post information that may well be essential to investors on our web site at In addition, to master more, remember to check out us on and comply with us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Fb at

DISCLOSURE Observe: The info contained in this launch is as of March 11, 2022. Pfizer assumes no obligation to update forward-on the lookout statements contained in this launch as the consequence of new details or potential activities or developments.

This release incorporates ahead-searching info about Pfizer’s acquisition of Arena, Pfizer’s I&I portfolio, like etrasimod, temanogrel and APD418, and predicted ideal-in-class and progress possible, which includes their possible added benefits, that involve sizeable risks and uncertainties that could induce actual outcomes to vary materially from those expressed or implied by these kinds of statements. Threats and uncertainties include things like, amid other points, challenges related to the capacity to comprehend the predicted advantages of the acquisition, together with the chance that the expected benefits from the acquisition will not be recognized or will not be realized inside of the envisioned time time period the threat that the corporations will not be built-in properly destructive effects of the consummation of the acquisition on the marketplace cost of Pfizer’s common inventory and/or operating outcomes sizeable transaction fees mysterious liabilities the danger of litigation and/or regulatory steps connected to the acquisition or Arena’s company other business results and uncertainties, which includes the effects of industry, marketplace, business, economic, political or regulatory ailments foreseeable future exchange and fascination charges modifications in tax and other laws, laws, fees and insurance policies long term organization mixtures or disposals the uncertainties inherent in study and advancement, together with the capacity to meet up with expected scientific endpoints, commencement and/or completion dates for medical trials, regulatory submission dates, regulatory approval dates and/or start dates, as very well as the risk of unfavorable new clinical facts and more analyses of present scientific facts hazards linked with interim info the threat that scientific demo data are issue to differing interpretations and assessments by regulatory authorities whether or not regulatory authorities will be content with the style and design of and benefits from the scientific scientific tests no matter whether and when drug applications may perhaps be filed in any jurisdictions for etrasimod, temanogrel, APD418 or any other investigational goods no matter if and when any these types of programs might be authorised by regulatory authorities, which will rely on myriad factors, which includes earning a resolve as to whether or not the product’s benefits outweigh its identified hazards and dedication of the product’s efficacy and, if approved, whether etrasimod, temanogrel, APD418 or any these other solutions will be commercially effective decisions by regulatory authorities impacting labeling, producing procedures, safety and/or other issues that could have an effect on the availability or industrial opportunity of etrasimod, temanogrel, APD418 or any such other products uncertainties concerning the effects of COVID-19 and competitive developments.

A further more description of pitfalls and uncertainties can be uncovered in Pfizer’s Yearly Report on Sort 10-K for the fiscal calendar year finished December 31, 2021 and in its subsequent reports on Type 10-Q, like in the sections thereof captioned “Chance Aspects” and “Ahead-Searching Information and Elements That Could Have an impact on Potential Outcomes”, as perfectly as in its subsequent studies on Variety 8-K, all of which are filed with the U.S. Securities and Trade Fee and readily available at and

Perspective resource model on


Media Relations:
+1 (212) 733-1226
[email protected]

Investor Relations:
+1 (212) 733-4848
[email protected]